Download Files:
TPN171
$680 – $5,600
Products Details
Product Description
– TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH)[1].
Web ID
– HY-128593
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C24H35N5O3
References
– [1]Wang Z, et al. Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. J Med Chem. 2019 May 23;62(10):4979-4990.
CAS Number
– 1229018-87-4
Molecular Weight
– 441.57
Compound Purity
– 99.41
SMILES
– CCCOC1=C(C2=NC(CC)=C(CC)C(N2)=O)C=C(NC(CN3CCN(C)CC3)=O)C=C1
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Phosphodiesterase (PDE)
Isoform
– PDE5
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
